🟠 Moderate Evidence
A 25-year register-based study of Danish women has identified a slightly elevated risk of meningioma—a typically benign tumour of the protective membranes surrounding the brain and spinal cord—associated with hormonal contraceptives containing a progestogen. The Danish Medicines Agency has raised a formal safety signal with the European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC), prompting a Europe-wide review of the risk-benefit profile of these widely used contraceptives.
Key takeaways
- Danish register-based study spanning 25 years found a modestly increased risk of meningioma in women using progestogen-containing contraceptives
- The absolute risk remains very low; meningiomas are rare, and most are benign
- The Danish Medicines Agency has escalated the finding to the European PRAC for formal pharmacovigilance assessment
- No immediate regulatory action has been taken, but the review may lead to updated product labelling or risk mitigation strategies
Study at a Glance
| Source | Danish Medicines Agency Register Study |
| Study type | Population-based cohort study using national health registers |
| Duration | 25 years of follow-up data |
| Population | Danish women aged 15–59 years |
| Country | Denmark (Nordic register data) |
Meningioma: A Rare but Growing Safety Concern
Regulatory escalation timeline and population scope of the Danish study
Source: Danish Medicines Agency, 2026 | Georgian Medical Journal News
What the evidence shows
The Danish Medicines Agency’s register-based analysis drew on national health records spanning 25 years to assess the association between progestogen-containing oral contraceptives and meningioma incidence. Register-based cohort studies are considered gold-standard population epidemiology tools for rare outcomes, because they capture entire populations without loss to follow-up and eliminate recall bias. The study identified a modestly elevated risk—described as “slightly increased”—in women using these contraceptives compared to non-users.
Meningiomas are tumours of the meninges (the three membranes that envelop the brain and spinal cord), and the vast majority are benign and slow-growing. They represent approximately 15% of all primary brain and central nervous system tumours in women, but absolute incidence remains low. For pharmaceutical safety monitoring, even modest relative risk increases in very rare conditions warrant formal pharmacovigilance review, particularly when millions of women use the medication globally.
The regulatory response: PRAC escalation
In response to the Danish findings, the European Medicines Agency (EMA)‘s PRAC—the committee responsible for evaluating pharmacovigilance signals across the EU and European Economic Area—has opened a formal assessment of the risk-benefit profile of all progestogen-containing hormonal contraceptives. This move does not constitute a recall or an immediate change in product prescribing; instead, it initiates a structured evaluation of the signal’s causality, magnitude, and clinical implications.
The PRAC assessment will consider whether the risk is confirmed in other populations, whether risk stratification is possible (e.g., by specific progestogen type, dose, or duration of use), and whether updated product information (labelling) or risk mitigation measures are warranted. Such reviews typically take several months to complete, with interim findings disseminated to healthcare authorities and healthcare professionals.
Clinical context and reassurance
Clinicians and patients should note that the absolute risk of meningioma remains very low even in users of progestogen-containing contraceptives. The benefits of hormonal contraception—including pregnancy prevention, reduced risk of ovarian and endometrial cancers, improved menstrual regulation, and treatment of hormonal conditions—remain substantial for most women. The Danish finding does not suggest an immediate need to discontinue these contraceptives, but rather highlights the importance of individualised risk-benefit discussion, particularly in women with personal or family history of brain tumours or other risk factors for meningioma.
For further information on hormonal contraceptive safety and clinical decision-making, clinicians are advised to await the EMA PRAC conclusion and any resulting regulatory communications. In the interim, existing product summaries of characteristics remain the authoritative prescribing source.
A 25-year Danish register study found a modestly elevated risk of meningioma in women using progestogen-containing oral contraceptives; the Danish Medicines Agency escalated this to the European PRAC for formal pharmacovigilance review.
— Danish Medicines Agency (2026)
What this means
Frequently asked questions
Should I stop taking my hormonal contraceptive immediately?
No. The absolute risk of meningioma associated with progestogen-containing contraceptives remains very low based on the Danish study. The benefits of contraception—pregnancy prevention and other health advantages—generally outweigh this rare risk for most women. Discuss your individual risk factors and preferences with your healthcare provider rather than stopping abruptly.
What is a meningioma and how serious is it?
A meningioma is a tumour of the meninges—the protective membranes surrounding the brain and spinal cord. Most meningiomas are benign (non-cancerous) and slow-growing, and many cause no symptoms. Even when symptomatic, most can be managed with surgery, radiation, or observation. Meningiomas are rare overall; the Danish study identified a modest increase in an already uncommon condition.
What happens next with regulatory oversight?
The European PRAC will conduct a formal pharmacovigilance assessment, which typically takes several months. The committee may request additional data from manufacturers, review safety reports from other populations, and evaluate whether risk mitigation measures are needed. Any conclusions will be communicated to healthcare authorities, healthcare professionals, and patients through updated product labelling or safety advisories.
This Danish register-based finding underscores the ongoing importance of post-authorisation safety surveillance for widely used medicines. As the EMA PRAC conducts its review, clinicians and patients should remain informed about developments while maintaining perspective on the rarity of meningiomas and the established benefits of hormonal contraception. Regulatory processes are designed to protect public health by balancing known benefits against emerging risks—and this case exemplifies that process in action.
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Editorial standards. This article was produced under the GMJ News editorial process, with oversight by the GMJ Editorial Board. Our editorial process. Spotted an error? Contact the editorial team.
